← All trials
NCT02895815
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 9, 2018
- Primary completion
- Feb 20, 2021
- Completion date
- Aug 19, 2022
- First posted
- Sep 12, 2016
- Last posted
- Dec 22, 2017
- Enrollment
- 0
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.